当前位置： SCI文献检索 > Clinical Lung Cancer期刊下所有文献 > The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography.

The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low-Dose Computed Tomography.

Abstract：

INTRODUCTION:Lung cancer screening (LCS) with low-dose computed tomography (LDCT) is recommended by the U.S. Preventive Services Task Force (USPSTF) in high-risk patients, but a minority of eligible people are screened. It is not clear whether knowledge of USPSTF recommendations among primary care physicians (PCP) affects utilization of LDCT. METHODS:A randomly selected sample of 1384 PCPs in Los Angeles County was surveyed between January and October 2015, using surveys sent by mail, fax, and e-mail. The response rate was 18% (n = 250). Training background, years in practice, practice type, and respondent demographics were collected. We analyzed results based on the response to a question on whether the USPSTF recommends the use of LDCT to screen high-risk individuals for lung cancer. RESULTS:A total of 117 (47%) PCPs responded that the USPSTF recommends LDCT for LCS. Of PCPs who were aware of USPSTF recommendations, 97% responded that CT was effective at reducing lung cancer mortality among individuals meeting eligibility criteria, compared with 90% who were unaware of guidelines (P = .02). A larger proportion of PCPs aware of guidelines ordered LDCT (71% vs. 38%, P < .001) and initiated a discussion on screening (86% vs. 62%, P < .001). Both groups of PCPs reported similar perceptions of barriers to screening, such as insurance coverage, risks of LCS, and cost to society. Practice size, training background, and years in practice did not affect knowledge of guidelines. DISCUSSION:Awareness of USPSTF recommendations for LDCT is associated with increased utilization of LDCT for screening. Educational interventions for PCPs may improve adherence with LCS recommendations.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Raz DJ,Wu GX,Consunji M,Nelson RA,Kim H,Sun CL,Sun V,Kim JY

doi

10.1016/j.cllc.2017.05.013

subject

Has Abstract

pub_date

2018-01-01 00:00:00

pages

51-57

issue

1

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(17)30148-1

journal_volume

19

pub_type

杂志文章

相关文献

Clinical Lung Cancer文献大全
  • Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.

    abstract：BACKGROUND:The programmed death 1/programmed death-ligand 1 (PD-L1) pathway reportedly is as an important factor determining effects of immunotherapy; however, its prognostic impact is controversial, and its association with the surrounding immune microenvironment has not yet been elucidated. PATIENTS AND METHODS:We r...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.01.013

    authors： Handa Y,Tsutani Y,Shiroma N,Kai Y,Mimae T,Miyata Y,Takeshima Y,Arihiro K,Okada M

    更新日期：2020-07-01 00:00:00

  • Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma.

    abstract：BACKGROUND:The optimal timing of thoracic radiation therapy (RT) in relation to chemotherapy is unknown in the treatment of nonmetastatic small cell lung cancer (SCLC). We analyzed the National Cancer Data Base (NCDB) to assess the effect on overall survival (OS) of RT timing with chemotherapy for patients with SCLC. ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.07.009

    authors： Wong AT,Rineer J,Schwartz D,Becker D,Safdieh J,Osborn V,Schreiber D

    更新日期：2017-03-01 00:00:00

  • The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.

    abstract：:The ability to reliably distinguish synchronous primary non-small-cell lung cancer (NSCLC) from intrapulmonary metastatic spread affects staging and treatment decisions in resected NSCLC. Adjuvant therapy for early-stage NSCLC is complicated and recommendations are primarily based on older data from trials that used n...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2015.03.004

    authors： Klempner SJ,Ou SH,Costa DB,VanderLaan PA,Sanford EM,Schrock A,Gay L,Ali SM,Miller VA

    更新日期：2015-09-01 00:00:00

  • Immune modulation as a therapeutic strategy for non-small-cell lung cancer.

    abstract：:Active tumor immunotherapy may provide hope for patients with non-small-cell lung cancer (NSCLC) because, in more than 20 years, current therapies have yet to change mortality statistics. Creating an efficacious vaccine involves selection of important tumor antigens and formulation of their immunogenic epitopes into a...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/clc.2008.s.003

    authors： Holt GE,Disis ML

    更新日期：2008-02-01 00:00:00

  • Lung cancer hormesis in high impact states where nuclear testing occurred.

    abstract：BACKGROUND:Hormesis is a favorable biological response to low toxin exposure. In the case of radiation, large doses are carcinogenic, but low doses might be protective. In the current study, we analyzed lung cancer incidence in high-impact radiation states where nuclear testing occurred and compared it with lung cancer...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2014.09.010

    authors： Lehrer S,Rosenzweig KE

    更新日期：2015-03-01 00:00:00

  • Undertreatment of elderly patients with non-small-cell lung cancer.

    abstract：:The absolute number of patients with lung cancer is rising as a result of our aging population. Until recently, clinicians have been reluctant to aggressively treat elderly patients with non-small-cell lung cancer (NSCLC) because of a lack of supportive data and concern for potential toxicity. Recently, evidence has e...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2005.n.031

    authors： Ng R,de Boer R,Green MD

    更新日期：2005-11-01 00:00:00

  • Computed tomography screening for lung cancer: applicability of an international protocol in a single-institution environment.

    abstract：BACKGROUND:The purpose of this study was to assess the applicability of an annual low-dose computed tomography (CT) screening program for lung cancer in a single institution in Israel, which has a relatively lower prevalence of lung cancer compared with other Western countries, and to examine stage distribution of dete...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2006.n.004

    authors： Shaham D,Breuer R,Copel L,Agid R,Makori A,Kisselgoff D,Goitein O,Izhar U,Berkman N,Heching N,Sosna J,Bar-Ziv J,Libson E

    更新日期：2006-01-01 00:00:00

  • ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer.

    abstract：BACKGROUND:ROS1 gene fusions cause several cancers by constitutively activating the ROS1 tyrosine kinase receptor. ROS1-targeted inhibitor therapy improves survival in the approximately 1% to 2% of patients with lung adenocarcinoma with ROS1 gene fusions. Although fluorescence in situ hybridization (FISH) is the standa...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2014.10.003

    authors： Boyle TA,Masago K,Ellison KE,Yatabe Y,Hirsch FR

    更新日期：2015-03-01 00:00:00

  • Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.

    abstract：BACKGROUND:Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors-erlotinib and gefitinib. PATIENTS AND METHODS:From 2008 to 2011, 130 ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.01.006

    authors： Zenke Y,Yoh K,Matsumoto S,Umemura S,Niho S,Ohmatsu H,Goto K,Ohe Y

    更新日期：2016-09-01 00:00:00

  • Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma.

    abstract：BACKGROUND:The benefits of immune checkpoint inhibitors for first-line treatment in patients with lung adenocarcinoma harboring EGFR mutations are unclear. The effects of ICIs depend on the tumor microenvironment (TME). Differences in TME properties between mutant and wild-type EGFR have not been fully characterized. ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2018.03.011

    authors： Gong Z,Chen J,Cheng JN,Sun C,Jia Q,Diao X,Zhu B

    更新日期：2018-09-01 00:00:00

  • CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status.

    abstract：INTRODUCTION:The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kir...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2015.05.009

    authors： Schuette W,Behringer D,Stoehlmacher J,Kollmeier J,Schmager S,Fischer von Weikersthal L,Schumann C,Buchmann J

    更新日期：2015-11-01 00:00:00

  • Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.

    abstract：INTRODUCTION:The effect of local therapy (LT) for oligoprogressive epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has not been well established. Forty-six patients with stage IIIB/IV EGFR-mutated NSCLC were treated by LT and continuing tyrosine kinase inhibitors (TKIs) for oligoprogr...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2017.04.002

    authors： Qiu B,Liang Y,Li Q,Liu G,Wang F,Chen Z,Liu M,Zhao M,Liu H

    更新日期：2017-11-01 00:00:00

  • Cancer treatments: can we find treasures at the bottom of the sea?

    abstract：:Because of the poor results observed after platinum-based first-line chemotherapy, research on new strategies for second-line treatment of advanced non-small-cell lung cancer (NSCLC) is warranted. Current research focuses on the development of new agents and the assessment of a combination of therapies, especially tho...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2009.n.041

    authors： Provencio M,Sánchez A,Gasent J,Gómez P,Rosell R

    更新日期：2009-07-01 00:00:00

  • Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

    abstract：BACKGROUND:Many patients diagnosed with stage IIIB (AJCC sixth edition; T4, N3, or both; no pleural effusion) non-small-cell lung cancer (NSCLC) are treated with curative intent, despite a low cure rate. Guidelines are required to help select patients for radical therapy so that the patients with little chance of cure ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.12.007

    authors： Russell K,Healy B,Pantarotto J,Laurie SA,MacRae R,Sabri E,Wheatley-Price P

    更新日期：2014-05-01 00:00:00

  • Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.

    abstract：:Gefitinib is a small-molecule agent specifically targeted to inhibit the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). Tumor responses have been achieved with gefitinib treatment in large, randomized monotherapy trials. In preclinical studies, gefitinib has shown additive and even supra-additive antitumo...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/clc.2003.s.011

    authors： Hammond LA

    更新日期：2003-09-01 00:00:00

  • Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms.

    abstract：:There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer (NSCLC), and thus adjuvant chemotherapy has been explored with the goal of eliminating occult metastases and consequently reducing the risk of recurrence. Although adjuvant chemotherapy confers a survival ad...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2011.06.002

    authors： Carbone DP,Felip E

    更新日期：2011-09-01 00:00:00

  • Multitargeted inhibitors in lung cancer: new clinical data.

    abstract：:Novel therapies have been added to the treatment arsenal of physicians treating lung cancer in recent years. Most promising are agents that target the major pathways involved in cancer evolution, mostly proliferation and angiogenesis. Some of these treatments have been shown to synergize with traditional chemotherapy ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2008.s.014

    authors： Bar J,Herbst RS,Onn A

    更新日期：2008-01-01 00:00:00

  • Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer.

    abstract：:During the past decade, the recognition of an ever-expanding list of driver oncogenic mutations in non-small-cell lung cancer has resulted in rapid therapeutic advances. Since the first description of the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement in 4% of case...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2016.05.006

    authors： Matikas A,Kentepozidis N,Georgoulias V,Kotsakis A

    更新日期：2016-11-01 00:00:00

  • Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.

    abstract：INTRODUCTION:We examined the effect of access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on survival for Asian female (AF) EGFR mutation-enriched patients with advanced lung adenocarcinoma. MATERIALS AND METHODS:We used the Surveillance Epidemiology and End Results database to s...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.08.008

    authors： Becker DJ,Wisnivesky JP,Grossbard ML,Chachoua A,Camidge DR,Levy BP

    更新日期：2017-01-01 00:00:00

  • The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.

    abstract：:The combination of chemotherapy and radiation has been validated for the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the results are still unsatisfactory, and there is a need to improve current treatment. One approach is to use new agents that have the potential to enhance the efficacy o...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/clc.2005.s.011

    authors： Edelman MJ

    更新日期：2005-10-01 00:00:00

  • Comorbidity Assessment Using Charlson Comorbidity Index and Simplified Comorbidity Score and Its Association With Clinical Outcomes During First-Line Chemotherapy for Lung Cancer.

    abstract：BACKGROUND:Limited data is available on comorbidity assessment in patients with lung cancer. The present prospective study assessed the prevalence and association of the Charlson comorbidity index (CCI) and simplified comorbidity score (SCS) with clinical outcomes in patients with newly diagnosed lung cancer undergoing...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.10.002

    authors： Singh N,Singh PS,Aggarwal AN,Behera D

    更新日期：2016-05-01 00:00:00

  • Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

    abstract：BACKGROUND:Afatinib is approved in the US, Europe, and several other regions for first-line treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Treatment-naive patients with advanced EGFRm+ NSCLC were randomized to afatinib (40 mg/d) versus...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2018.03.009

    authors： Wu YL,Sequist LV,Tan EH,Geater SL,Orlov S,Zhang L,Lee KH,Tsai CM,Kato T,Barrios CH,Schuler M,Hirsh V,Yamamoto N,O'Byrne K,Boyer M,Mok T,Peil B,Märten A,Chih-Hsin Yang J,Paz-Ares L,Park K

    更新日期：2018-07-01 00:00:00

  • Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography.

    abstract：INTRODUCTION:We set out to investigate whether volumetric tumor measurements allow for a prediction of treatment response, as measured by patient survival, in patients with advanced non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS:Patients with nonresectable NSCLC (stage III or IV, n = 100) who were repeatedl...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.11.001

    authors： Knollmann FD,Kumthekar R,Fetzer D,Socinski MA

    更新日期：2014-03-01 00:00:00

  • Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.

    abstract：BACKGROUND:Real-world data have suggested a detrimental effect of steroid use in patients with advanced non-small-cell lung cancer (NSCLC) receiving immunotherapy. However, previous studies included heterogeneous cohorts of patients receiving different lines of treatment with several immuno-oncology agents and various ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.09.017

    authors： Mountzios G,de Toma A,Economopoulou P,Friedlaender A,Banini M,Lo Russo G,Baxevanos P,Roila F,Banna GL,Christopoulou A,Jimenez B,Collazo-Lorduy A,Linardou H,Calles A,Galetta D,Addeo A,Camerini A,Pizzutilo P,Kosmidis P

    更新日期：2020-10-14 00:00:00

  • Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.

    abstract：BACKGROUND:Molecular studies have demonstrated actionable driver oncogene alterations are more frequent in never-smokers with non-small-cell lung cancer (NSCLC). The etiology of these driver oncogenes in patients with NSCLC remains unknown, and environmental tobacco smoke (ETS) is a potential cause in these cases. MAT...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2017.01.005

    authors： Soo RA,Kubo A,Ando M,Kawaguchi T,Ahn MJ,Ou SI

    更新日期：2017-09-01 00:00:00

  • Complications of ablative therapies in lung cancer.

    abstract：:Two cases of complications secondary to the use of microwave ablation (MWA) in non-small-cell lung cancer (NSCLC) are discussed herein. The first case involves a 62-year-old man with stage IB NSCLC who declined surgery and pursued MWA. Within 7 months, he had residual disease at the MWA treatment site, and surgery was...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2008.n.019

    authors： Padda S,Kothary N,Donington J,Cannon W,Loo BW Jr,Kee S,Wakelee H

    更新日期：2008-03-01 00:00:00

  • Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.

    abstract：BACKGROUND:Several studies have assessed the expression of programmed death-ligand 1 (PD-L1) in resected surgical specimens of non-small-cell lung cancer (NSCLC). However, the expression of PD-L1 in smaller biopsy samples of advanced NSCLC has not been reported. PATIENTS AND METHODS:A total of 79 patients with NSCLC a...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.03.008

    authors： Kitazono S,Fujiwara Y,Tsuta K,Utsumi H,Kanda S,Horinouchi H,Nokihara H,Yamamoto N,Sasada S,Watanabe S,Asamura H,Tamura T,Ohe Y

    更新日期：2015-09-01 00:00:00

  • Quality of life and the treatment of advanced lung cancer.

    abstract：:Lung cancer is the leading cause of cancer deaths worldwide, with the majority of patients presenting with advanced disease. Despite the introduction of newer therapeutic agents and modest survival improvement, the overall prognosis for these patients is poor. The goals of therapy should therefore include improvement ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2003.n.018

    authors： Plunkett TA,Chrystal KF,Harper PG

    更新日期：2003-07-01 00:00:00

  • Phase II study of sequential treatment of advanced non-small-cell lung cancer: three cycles of high-dose epirubicin plus cisplatin followed by weekly vinorelbine.

    abstract：:Previous phase I, II, and III studies on high-dose epirubicin (HDEPI), alone or in combination with cisplatin (CP), indicate an interesting activity of this drug in the treatment of non-small-cell lung cancer (NSCLC). However, the toxicological profile of HDEPI limits its prolonged use. In our experience, vinorelbine ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2001.n.017

    authors： Guaraldi M,Marino A,Pannuti F,Farabegoli G,Martoni A

    更新日期：2001-08-01 00:00:00

  • Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.

    abstract：INTRODUCTION:The lung is a heterogeneous organ with relative overperfusion of the lung bases. We determined whether a lower lobe primary tumor location was associated with poor outcomes in the setting of stage I non-small-cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND ME...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.09.001

    authors： Shaverdian N,Veruttipong D,Wang J,Kupelian P,Steinberg M,Lee P

    更新日期：2017-03-01 00:00:00